Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Suzhou Ribo Licenses siRNA Delivery System from Life Techologies

publication date: Jun 19, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Suzhou Ribo Life Sciences and Life Technologies of California have stuck a deal giving Ribo exclusive China rights to develop and manufacture siRNA therapeutics using Life's Invivofectamine® Rx delivery technology. Life Technologies will receive milestones and royalties for each drug that Ribo develops. Ribo’s first product is a treatment for hepatitis B. Invivofectamine® was originally produced as a research tool for knocking out genes in small-animal research models. Invivofectamine® Rx is based around a new class of lipid molecules that is 100-fold more powerful than the research product, while being less toxic, according to Life. More details....

Stock Symbol: (NSDQ: LIFE)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...